{"url_path":"/sec/acad/8-k/2026-09-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1070494/0001193125-26-389400-index.html","accession_number":"0001193125-26-389400","cik":"0001070494","ticker":"ACAD","issuer_name":"ACADIA PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1070494/0001193125-26-389400-index.html","primary_entity_key":"0001070494","primary_entity_name":"ACADIA PHARMACEUTICALS INC"},"word_count":91,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\nNumber\n  \n\nDescription\n\n99.1\n  \n[Notice of Pendency and Proposed Settlement of Derivative Matters.](d143428dex991.htm)\n\n99.2\n  \n[Stipulation and Agreement of Settlement.](d143428dex992.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nAcadia Pharmaceuticals Inc.\n\nDate: September 11, 2026\n \n\n \nBy:\n \n\n/s/ Jennifer J. Rhodes\n\n \n\n \n\n \n\nJennifer J. Rhodes\n\nExecutive Vice President, Chief Legal Officer"}